DBV TECHNOLOGIE/S (DBVT) versus BIONDVAX PHARMA/S (BVXV) Head-To-Head Contrast

Share on StockTwits

DBV TECHNOLOGIE/S (NASDAQ:DBVT) and BIONDVAX PHARMA/S (NASDAQ:BVXV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares DBV TECHNOLOGIE/S and BIONDVAX PHARMA/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DBV TECHNOLOGIE/S N/A N/A N/A
BIONDVAX PHARMA/S N/A -168.28% -74.56%

Analyst Recommendations

This is a breakdown of current ratings and price targets for DBV TECHNOLOGIE/S and BIONDVAX PHARMA/S, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV TECHNOLOGIE/S 0 1 5 0 2.83
BIONDVAX PHARMA/S 0 0 0 0 N/A

DBV TECHNOLOGIE/S currently has a consensus price target of $36.40, indicating a potential upside of 159.26%. Given DBV TECHNOLOGIE/S’s higher possible upside, equities research analysts plainly believe DBV TECHNOLOGIE/S is more favorable than BIONDVAX PHARMA/S.

Earnings and Valuation

This table compares DBV TECHNOLOGIE/S and BIONDVAX PHARMA/S’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DBV TECHNOLOGIE/S $13.45 million 59.54 -$166.93 million ($3.37) -4.17
BIONDVAX PHARMA/S N/A N/A -$9.96 million ($1.98) -2.86

BIONDVAX PHARMA/S has lower revenue, but higher earnings than DBV TECHNOLOGIE/S. DBV TECHNOLOGIE/S is trading at a lower price-to-earnings ratio than BIONDVAX PHARMA/S, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

45.4% of DBV TECHNOLOGIE/S shares are owned by institutional investors. Comparatively, 6.9% of BIONDVAX PHARMA/S shares are owned by institutional investors. 15.3% of DBV TECHNOLOGIE/S shares are owned by insiders. Comparatively, 6.0% of BIONDVAX PHARMA/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

DBV TECHNOLOGIE/S has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, BIONDVAX PHARMA/S has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Summary

DBV TECHNOLOGIE/S beats BIONDVAX PHARMA/S on 8 of the 11 factors compared between the two stocks.

About DBV TECHNOLOGIE/S

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

About BIONDVAX PHARMA/S

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

IMPINJ  Upgraded to Buy by ValuEngine
IMPINJ Upgraded to Buy by ValuEngine
Xerox  Downgraded by ValuEngine to Strong Sell
Xerox Downgraded by ValuEngine to Strong Sell
Energi  Price Hits $1.21 on Exchanges
Energi Price Hits $1.21 on Exchanges
NuBits Hits Market Capitalization of $437,069.00
NuBits Hits Market Capitalization of $437,069.00
Eaton Vance  Sets New 52-Week Low at $34.55
Eaton Vance Sets New 52-Week Low at $34.55
FCB Financial  Reaches New 12-Month Low at $33.27
FCB Financial Reaches New 12-Month Low at $33.27


Leave a Reply

 
© 2006-2018 Zolmax.